Key Takeaways Pfizer has advanced oncology drugs like vepdegestrant, atirmociclib and sigvotatug vedotin.The company expects eight or more oncology blockbusters in its portfolio by 2030.Pfizer gained nine FDA approvals in 2023 and added a gene therapy approval in 2024.Pfizer (PFE) has strengthened its R&D pipeline through M&A deals and clinical trial success over the past decade.Pfizer has particularly advanced its oncology pipeline with several candidates entering late-stage development. Key oncology candi ...